Sunshine Care
SunshineCare.Online

Sunshine Care Virtual Clinics will open its first location using mainly ReStore Store/Habitat for Humanity materials, and plans on continuing the protocol. "We plan an aggressive clinic opening schedule, in rural and suburban areas along with franchising. Our plan is to always recommend utilizing ReStore Stores/Habitat for Humanity locations in remodeling and construction," says company CEO Rusty McMurray.

"Using local ReStore Stores/Habitat for Humanity serves as a give back to the local community we serve, cuts the lag time in ordering and delivering needed materials, plus lowers the construction budget," continues McMurray. 

Sunshine Care Virtual Clinics and SunshineCare.Online are companies created from the result of prior ObamaCare Innovation grant programs designed to help create an improved quality of life and lower the cost of care for patients. These ObamaCare innovation grants helped provide important foundational knowledge to create new billing codes to allow practices like Sunshine Care to grow and improve outcomes for patients. 

These payment sources for medical providers exist today, but for whatever reason, providers have been slow to adopt them. Sunshine Care over the last five years has served and improved the quality of life using these ObamaCare reimbursements to serve almost 20,000 Oklahomans, and reduced patient rehospitalizations by thousands, thus lowering the cost of care and improving outcomes.

"Currently, we are licensed in about a dozen states and adding more each week. We are planning our expansion model around ReStore Store/Habitat for Humanity locations across the country. Our only hope is to become a living part of every community we serve," says Rusty McMurray Sunshine Care CEO.

WHILL model F and C2 with Stealth Accessories
WHILL model F and C2 with Stealth Accessories

WHILL, Inc., award-winning provider of electric mobility chairs, and Stealth Products LLC, announced a new partnership whereby seating and positioning options have been curated specifically for the WHILL model C2 power chair to address a wider range of mobility issues for consumers.

After testing dozens of customization options, WHILL and Stealth have revealed a product mix of over 50 SKUs from headrests to lap belts, all specifically compatible with the WHILL model C2.  WHILL and Stealth will continue to expand product offerings as more customer needs are identified. 

"With its compact size, patented omni-wheels, remote app control, and advanced battery technology, the award-winning WHILL model C2 allows users to explore the world effortlessly," said Satoshi Sugie, CEO of WHILL. "The new partnership with Stealth Products allows us to customize that experience even more to address specialized mobility issues and continue to reduce barriers for our customers."

"Stealth is excited to enter into this partnership with WHILL," said Scott Brown, National Sales Manager for Stealth Products. "Our mutual commitment to providing high-quality solutions for individuals with specialized needs is the primary motivator to create a more comprehensive seating and mobility outcome for all customers."  

The WHILL model C2  received full FDA approval earlier this year acknowledging its ability to be adaptive and fitted to a variety of needs. Sylvia Longmire, brand ambassador and long-time user of the product explains: "As a disabled veteran with an active lifestyle, I know FDA approval of the WHILL model C2 will make a hugely positive difference in the lives of fellow veterans receiving care through the Veterans Administration."

WHILL power chairs outfitted with Stealth seating and positioning options will be featured at MedTrade East in Atlanta Oct. 24-26, 2022. A full range of Stealth products specially curated for WHILL power chairs can be found at WHILL dealers nationwide and a virtual catalog can be found online at https://whill.inc/us/more-possibilities-more-comfort/.

About WHILL, Inc.  WHILL connects the world with short-distance mobility products and services and provides Mobility-as-a-Service solutions, offering autonomous and manual transportation services that make public spaces like airports, vacation destinations, and convention centers more accessible. WHILL now offers products and services in over 20 countries and regions globally. https://whill.inc

About Stealth Products  Launched in 1999, Stealth Products is a U.S. manufacturer of versatile, high-quality head and neck positioning systems, as well as switch site location hardware. With consistent growth for 23 years and distributors in 22 countries, Stealth designers and engineers have been able to produce nearly any unique product requested, resulting in a culture of continuous innovation to improve the lives of their customers.  

Be the Match
Be the Match

The AcCELLerate Forum, a joint partnership between the American Society for Transplantation and Cellular Therapy (ASTCT™), the Center for International Blood and Marrow Transplant Research® (CIBMTR®), and the National Marrow Donor Program® (NMDP)/Be The Match®, brings key stakeholders together to identify ongoing needs and opportunities in cell and gene therapy for advocacy, measurement of value and impact and sustainability. The virtual workshop on Nov. 17-18, 2022, joins providers, payers, government agencies and industry members who will work together to define essential factors needed to create a sustainable cell and gene therapy ecosystem. 

"NMDP/Be The Match is proud to be one of the sponsors of this important forum that has interests for all key stakeholders across the ecosystem," said Jeffery Auletta, M.D., Senior Vice President, Patient Outcomes and Experience, of NMDP/Be The Match, Chief Scientific Director, CIBMTR. "Our established relationships with a global network of transplant centers and cell and gene therapy developers uniquely position NMDP/Be The Match to bring these experts together to identify the needs and opportunities in this field for advocacy, measurement, and sustainability."

Dr. Auletta will join industry and transplant center partners and other professionals to address the question, "Are Center-Specific Outcomes Possible for CAR T-cell Immunotherapy?" The participants will focus on the perspectives of the payer, data acquisition and analysis, and center perspectives in defining outcomes for CAR T cells. They will also discuss healthcare inequity, specifically barriers to access and their impact on cell therapy outcomes. The speakers will incorporate the evolving cell therapy landscape from industry collaboration to clinical trials and real-world treatment in their presentations and in a moderator-led roundtable with attendee participation. Visit the event website to register and see the complete schedule and list of presenters.

In addition to NMDP/Be The Match, the event co-hosts include:

The American Society for Transplantation and Cellular Therapy (ASTCT) is an international professional membership association of more than 3,000 physicians, investigators, and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. For more information about ASTCT, visit www.astct.org and follow us on Twitter, @ASTCT.

The CIBMTR, a research collaboration between the NMDP/Be The Match and the Medical College of Wisconsin, facilitates critical cellular therapy research through a clinical database of more than 600,000 patients from more than 350 centers worldwide, with a biospecimen repository of more than 195,000 samples. 

Background:

The National Marrow Donor Program® (NMDP)/Be The Match® is the leading global partner working to save lives through cellular therapy. With 35 years of experience managing the most diverse registry of potential unrelated blood stem cell donors and cord blood units in the world, NMDP/Be The Match is a proven partner in providing cures to patients with life-threatening blood and marrow cancers and diseases. Through their global network, they connect centers and patients to their best cell therapy option—from blood stem cell transplant to a next-generation therapy—and collaborate with cell and gene therapy companies to support therapy development and delivery through Be The Match BioTherapies®. NMDP/Be The Match is a tireless advocate for the cell therapy community, working with hematologists/oncologists to remove barriers to consultation and treatment, and supporting patients through no-cost programs to eliminate non-medical obstacles to cell therapy. In addition, they are a global leader in research through the CIBMTR®—a collaboration with the Medical College of Wisconsin, investing in and managing research studies that improve patient outcomes and advance the future of care.

Clinicians with the Gastrointestinal Eosinophilic Disease Program at the Digestive Health Institute, Children's Hospital of Colorado, performed the Esophageal String Test^® (EST) on a patient in early September. The test will be offered regularly at the hospital.

The EST was also performed on patients in the Eosinophilic Gastrointestinal Disease Clinic at Phoenix Children's Hospital. 

"I am now beyond thrilled to use this new esophageal surveillance technique at Phoenix Children's and for my patients with eosinophilic gastrointestinal disorders. The EST is a game-changer for my patients who are looking for a less invasive and less expensive way to screen their disease activity," said Dr. Shauna Schroeder, Medical Director for the Eosinophilic Gastrointestinal Disease Clinic at Phoenix Children's Hospital. She further stated "Having trained in Denver, I had experience using the EST as a research tool in patients with eosinophilic esophagitis. I am now able to more granularly adjust medications and diets improving the care of my patients with eosinophilic esophagitis."

The Esophageal String Test^® utilizes a simple collection device, the EnteroTracker^®, to collect upper gastrointestinal samples from adults and children.  The samples are sent to an independent reference lab for analysis of disease activity. Several other clinics around the country are planning to offer the test soon.

About EnteroTrack 

EnteroTrack, an early-stage company, develops simple-to-use, minimally invasive technologies to sample gastrointestinal (GI) mucosal content that can be assayed for various biomarkers of disease. The company's platform technology, the EnteroTracker^® is initially being used to support clinical monitoring of Eosinophilic Esophagitis in adults and children without need for sedation, advanced training, or complex procedures. Clinical studies evaluating the utility of the EnteroTracker^® for additional applications including Esophageal Adenocarcinoma, Barrett's Esophagus, GERD, GI microbiome, food allergy testing, and others are currently underway.

GB Sciences

Gb Sciences, Inc. ("GbS"; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has received positive preclinical results in an interim report from its study using preclinical zebrafish models of stress at the National Research Council of Canada (NRC). GbS' proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study. The NRC is testing GbS' proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending PhAROS™ (Phytomedical Analytics for Research Optimization at Scale) platform to identify these combinations of plant compounds for novel drug candidates. These are the company's first non-cannabis formulations to advance in preclinical studies.

"We have achieved an important milestone in the development of our novel, kava-inspired anxiety formulations. Not only did some of our formulations achieve statistical significance in the animal model, but these minimum essential mixtures also demonstrated synergy by significantly outperforming the individual active ingredients within our minimum essential mixture formulations," said Dr. Andrea Small-Howard, Gb Sciences' President and Chief Science Officer. "This preclinical data also confirms that our PhAROS™ platform was capable of yielding concrete, potentially effective, plant-inspired combination drugs."

For these novel psychotropic drug candidates, the Gb Sciences research team used the PhAROS™ platform to identify new ingredients to improve upon an initial formulation for anxiety based on traditional medicine. The original plant mixture was derived from the kava plant, but some elements of kava are thought to cause liver toxicity. PhAROS™ identified ingredients from the Piper plant family as a substitute for the functionality of the ingredients in question without the potentially adverse safety profiles of those original ingredients. The Piper plant family includes pepper plants that are used worldwide in traditional medicines.

The PhAROS^TM platform is a revolutionary, AI-driven science gateway and virtual research environment for drug discovery. With its data analytics and machine learning capabilities, PhAROS™ allows Gb Sciences to greatly reduce the time and money required to bring novel, plant-inspired formulations to market. PhAROS™ represents a breakthrough combination of data sciences and traditional plant-based medicines. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The 'plant-inspired' active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com. 

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Media Contact

Alexis Quintal

[email protected]